Latest Conference Articles

Davidow discussed how a new cohort study has helped support findings of an older European study and the need for a prospective trial to confirm the increased risk.

Yehuda Handelsman, MD reflects on the WCIRDC 2024’s comprehensive approach to advancing cardiometabolic care through multidisciplinary collaboration.

Yehuda Handelsman, MD highlights insulin resistance’s role in cardiometabolic disease and introduces DCRM 2.0 as a global, multi-specialty care framework.

Weisinger discussed findings from the largest cohort of patients with iTTP treated with Obinutuzumab.

Nathan D. Wong, MPH, PhD discusses the evolution of Lp(a) in risk assessment, given its role as a genetic risk factor for cardiovascular complications.

Laurence Sperling, MD described the evolving role of cardiologists in obesity care, particularly with the increasing adoption of therapies such as GLP-1 agonists.

Laurence Sperling, MD shares insights into a multi-disciplinary approach to the management of obesity from the perspective of a cardiologist.

Schafer Boeder, MD describes the potential role and safety of adjunctive therapy, including SGLT2 inhibitors and GLP-1 agonists, for patients with T1D.

Real-world data from 18,710 MASH patients highlight the impact of comorbidities, biomarkers, and region on mortality, with 70% of deaths CVD-related.

Machine learning models improve accuracy in detecting MASH with F2-F3 fibrosis, surpassing noninvasive tests in sensitivity, specificity, and predictive value.

Matthew J. Budoff, MD describes bridging the gap between atherosclerosis and osteoporosis through advanced Imaging techniques.

Observational data point to aldosterone dysregulation as an underrecognized risk factor for hypertension and confirm T2D as a known risk factor.

Alice Cheng, MD, discusses the impact of diabetes on cognitive function and the emerging role of diabetic drug classes in dementia care.

Orly Vardeny, PharmD, MS explores the efficacy of nonsteroidal MRAs in heart failure with mildly reduced or preserved ejection fraction in the FINE-ARTS trial.

Matthew J. Budoff, MD discusses the effects of obesity and cardiometabolic complications in the contemporary management of type 1 diabetes.

Jennifer B. Green, MD highlights the successful implementation of evidence-based therapies for high-risk patients with type 2 diabetes.

Ralph A. DeFronzo, MD discusses the Noxious Nine and the impact of hypercortisolism on difficult-to-control type 2 diabetes.

Matthew Weir, MD discusses how a multidisciplinary approach is reshaping CKD management, with a focus on mitigating cardiovascular events.

Matsushita discussed findings from the OLE FRONTIER4 study of Mim8.

Matino discussed data from the phase 3 BASIS study evaluating the recently approved Hympavzi.

Patients with hypercortisolism and difficult-to-control type 2 diabetes who received mifepristone exhibited a significant HbA1c improvement in the Phase 4 trial.

Elevated blood insulin levels and insulin resistance each contributed to an elevated risk of colorectal cancer, a new study finds.

Samelson-Jones discussed follow-up data of up to 6 years with investigations of fidanacogene elaparvovec.

Bernaudin discussed the Drepagreffe-1 and 2 studies and improvements seen over 10 years of follow-up.

Real-world clinical data from the Adelphi PNH II Disease Specific Programme were reported at ASH 2024.

Danicopan add-on therapy demonstrated more favorable safety in the ALPHA trial than pegcetacoplan did in the PEGASUS trial in a new analysis.

Appiah-Kubi also noted that despite elevated HbF levels, very young children with SCA already had anemia and reticulocytosis.

Pipe discussed findings from the open-label extension of the ATLAS studies at ASH 2024.

At ASH 2024, Annette von Drygalski, MD, PharmD, described the paradigm shift that has taken place in hemophilia over the past decade.

Piatek shared the latest data update from the phase 3 ALPHA study at the ASH 2024.